id: NEW:metformin_treatment_to_NEW:gastrointestinal_adverse_events
name: Metformin Treatment â†’ Gastrointestinal Adverse Events
from_node:
  node_id: NEW:metformin_treatment
  node_name: Metformin Treatment
to_node:
  node_id: NEW:gastrointestinal_adverse_events
  node_name: Gastrointestinal Adverse Events
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Metformin administered as insulin sensitizer for PCOS treatment'
- 'Step 2: Drug absorbed through gastrointestinal tract causing local irritation'
- 'Step 3: GI adverse effects (nausea, diarrhea, abdominal discomfort) develop'
- 'Step 4: Adverse events limit treatment adherence and tolerability'
evidence:
  quality_rating: A
  n_studies: 6
  primary_citation: 'Fabio Facchinetti et al. 2019. "Short-term effects of metformin and myo-inositol
    in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.."
    https://doi.org/10.1080/09513590.2018.1540578'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 6 RCTs comparing MET to MI
  - Studies conducted from 1994-2017 identified via MEDLINE, Cochrane Library, PubMed
  - Individual study citations available in full-text systematic review
  doi: 10.1080/09513590.2018.1540578
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'Meta-analysis of 6 RCTs (355 patients) found strong evidence that women receiving metformin
  had 5.17 times higher risk of adverse events compared to those receiving myo-inositol (RR=5.17, 95%
  CI: 2.91-9.17, p<.001), primarily gastrointestinal in nature.'
quantitative_effects:
  effect_size:
    value: 5.17
    type: relative_risk
    ci_lower: 2.91
    ci_upper: 9.17
  p_value: 0.001
  sample_size: 355
structural_competency:
  equity_implications: This mechanism relates to healthcare access and treatment tolerability. Adverse
    effects from first-line treatments can create barriers to care, particularly for women without resources
    to manage side effects or access alternative treatments. The availability of better-tolerated alternatives
    like myo-inositol may improve treatment adherence and outcomes, especially in resource-limited settings.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.984184'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
